New treatment offers hope for an incurable disease
New drug slows lung disease idiopathic pulmonary fibrosis by 50 per cent. – The Hamilton Spectator (ON – August 24, 2015)
Greater hope for a longer life
The approval by Health Canada of a new drug to treat people with idiopathic pulmonary fibrosis (IPF) is a step closer to one day finding a cure. – Brant News (ON – July 20, 2015)
New drug for IPF gives patients hope
It’s just a small capsule, but the power a new drug called OFEV has to create hope for patients living with Idiopathic Pulmonary Fibrosis (IPF) is so much bigger than what would fit in the palm of your hand.
“I thank God for these drugs. That is what gives me hope,” said Jacqui Bowick-Sandor of Smiths Falls who was diagnosed with IPF in 2011. – Inside Ottawa Valley (ON – July 15, 2015)
Health Canada approves OFEV™ (nintedanib) for the treatment of idiopathic pulmonary fibrosis
IPF causes progressive and permanent scarring of the lungs, and over time it becomes difficult to take a deep breath. Dr. Martin Kolb explains.
New treatment option provides hope for Canadians living with fatal lung disease
BURLINGTON, ON July 6, 2015 /CNW/ – Boehringer Ingelheim Ltd. announced today that on June 24, 2015 Health Canada approved OFEV™ (nintedanib) to treat idiopathic pulmonary fibrosis (IPF) in adults. OFEV™ has been clinically proven to reduce the decline in lung function in IPF patients.
IPF is a debilitating and fatal lung disease, which causes progressive, irreversible scarring of the lungs, resulting in lung function decline and difficulty breathing. There is no cure. There are approximately 5,000 to 15,000 Canadians currently living with IPF, and the approval of OFEV™ offers IPF patients a new treatment option to manage this fatal disease.
“The approval of OFEV™ is a significant advancement for IPF patients, offering a proven treatment option to people living with this disease,” says Dr.Martin Kolb, M.D. PhD, Director, Division of Respirology at McMaster University. “Not only does OFEV™ offer another treatment choice for IPF patients to manage their disease, it has been shown to significantly reduce the risk of adjudicated acute exacerbations, which can be deadly.”
The symptoms of IPF – shortness of breath, dry hacking cough, “crackling” sounds in the lungs, and cyanosis (blue lips) – can have a significant impact on quality of life, and make it difficult to perform everyday activities. The median survival rate for people with IPF is two to three years after diagnosis; however, early and accurate diagnosis can help to ensure access to appropriate care.
“The Canadian Pulmonary Fibrosis Foundation welcomes the approval of OFEV™ as a new treatment option for IPF. Every advancement in treatment brings us one step closer to finding a cure, and putting an end to early death from IPF,” says Robert Davidson, President, Canadian Pulmonary Fibrosis Foundation (CPFF). “We must now support efforts to ensure that Canadians have full and timely access to this treatment in a disease area with few choices.”
There is new hope for IPF patients with the Health Canada approval of OFEV™ (nintedanib) for IPF.
OFEV™ was approved on June 24, 2015 and we’ll have more information about availability soon.
With the approval of OFEV™, patients who are diagnosed with IPF now have a choice of therapy. Working with their doctor, patients with IPF can determine which treatment option is right for them.
The Canadian Pulmonary Fibrosis Foundation will be working to ensure affordable access to this treatment in all the provinces.
If you have any questions about this treatment and its availability please contact the Boehringer Ingelheim Customer Care Team at 1-800-263-2425.